MD Anderson Cancer Center and Nexo Therapeutics have entered a multi-year strategic collaboration that aligns the technology and capabilities of each organization at the earliest stages of drug discovery and development, with the aim of advancing cancer therapies against previously undruggable targets.
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.
